Home Newsfeeds Barclays Maintains Underweight on Cognizant Tech Solns, Raises Price Target to $53

Barclays Maintains Underweight on Cognizant Tech Solns, Raises Price Target to $53

Barclays analyst Ramsey El-Assal maintains Cognizant Tech Solns (NASDAQ:CTSH) with a Underweight and raises the price target from $45 to $53.

byBenzinga Newsdesk

February 6, 2023

1 minute read

Barclays analyst Ramsey El-Assal maintains Cognizant Tech Solns (NASDAQ:CTSH) with a Underweight and raises the price target from $45 to $53.

One-Two Punch for T-Mobile: Secures DoD Contract & Uber Deal

By Lekha Gupta

June 13, 1:23 PM

T-Mobile selected by U.S. Navy for $2.67 billion contract for wireless solutions. Partnership with Uber allows expansion of interactive screens in rideshare vehicles.

PKW

Immix Biopharma Reports 2nd Interim Clinical Trial Data Readout In Relapsed/Refractory Metastatic Colorectal Cancer In Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial

By Benzinga Newsdesk

July 17, 9:37 AM

Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal

IMMX

Tronox Announces CEO Tim Carlson To Retire, John Srivisal Named Successor

By Bill Haddad

December 15, 8:35 AM

STAMFORD, Conn., Dec. 15, 2022 /PRNewswire/ -- Tronox Holdings plc (NYSE:TROX) ("Tronox" or the "Company"), the world's leading integrated manufacturer of titanium dioxide pigment, today

TROX

Pepe Up 6% And Trader Sees ‘Some Very Good Levels For Fresh Set Ups’

By Khyathi Dalal

May 9, 12:09 PM

Crypto traders express optimism about Pepe (CRYPTO: PEPE) despite a recent pullback, with some anticipating a powerful move towards all-time high levels.

$PEPE

Barclays Maintains Underweight on Cognizant Tech Solns, Raises Price Target to $53

Related Posts

One-Two Punch for T-Mobile: Secures DoD Contract & Uber Deal

Immix Biopharma Reports 2nd Interim Clinical Trial Data Readout In Relapsed/Refractory Metastatic Colorectal Cancer In Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial

Tronox Announces CEO Tim Carlson To Retire, John Srivisal Named Successor

Pepe Up 6% And Trader Sees ‘Some Very Good Levels For Fresh Set Ups’